Skip to main
SXTP

SXTP Stock Forecast & Price Target

SXTP Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

60 Degrees is a specialty pharmaceutical company focused on developing and commercializing new therapies for infectious diseases. Its three primary products, Tafenoquine, Celgosivir, and Australian Chestnut Extracts, have shown strong potential in treating various diseases. However, the company faces risks such as limited visibility on regulatory approvals and potential dilution from future capital raises. Despite these risks, the company's strong pipeline and potential for high growth make it an attractive investment opportunity.

Bears say

60 Degrees is facing challenges in generating revenue, with a Q1 FY26 revenue miss and a high annual burn rate. While the company has raised some financing through ATM sales, its cash position is still low and it may need to continue raising equity capital to fund its operations. Additionally, the company's expansion efforts for ARAKODA may not lead to significant revenue growth in the near term, as partnerships with GoodRx and Runway Health are focused on improving affordability and patient access rather than driving sales.

SXTP has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of 60 Degrees Pharmaceuticals Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About 60 Degrees Pharmaceuticals Inc (SXTP) Forecast

Analysts have given SXTP a Strong Buy based on their latest research and market trends.

According to 2 analysts, SXTP has a Strong Buy consensus rating as of Sep 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $13.85, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $13.85, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

60 Degrees Pharmaceuticals Inc (SXTP)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.